Inhibition of telomerase activity by HDV ribozyme in cancers
2011

Inhibition of Telomerase Activity by HDV Ribozyme in Cancers

publication Evidence: moderate

Author Information

Author(s): Lu Yingying, Gu Junchao, Jin Dachuan, Gao Yanjing, Yuan Mengbiao

Primary Institution: Beijing Friendship Hospital affiliated to Capital Medical University

Hypothesis

Can HDV ribozyme effectively inhibit telomerase activity in cancer cells?

Conclusion

The HDV ribozyme is an effective strategy for gene therapy, significantly reducing telomerase activity in cancer cells.

Supporting Evidence

  • The HDV ribozyme showed a maximum cleavage ratio of about 70.4% against telomerase RNA.
  • Transfection of HDV ribozyme into cancer cells led to a significant drop in telomerase activity to 10% of the original level.
  • Ribozyme-transfected cells exhibited increased apoptosis and cell cycle arrest.

Takeaway

This study shows that a special RNA molecule can stop cancer cells from growing by cutting their telomerase, which helps them live longer.

Methodology

The study involved designing and synthesizing an HDV ribozyme, transfecting it into cancer cells, and measuring its effects on telomerase activity and cell growth.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/1756-9966-30-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication